Overview: Since the treatment modalities for AML have remained relatively stagnant for decades, the approval of enasidenib is much needed as it affords patients a first-in-class, oral, single-agent targeted therapy for a difficult to treat diagnosis. This application-based continuing pharmacy education course provides a ‘journal club format’ discussion for pharmacists and student pharmacists to evaluate the phase 1/2 trial of enasidenib. Participate to review the safety and efficacy of enasidenib and discuss its potential in the evolving milieu of AML treatment.
